| Name | Title | Contact Details |
|---|
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
NDD Medical Technologies is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LC Sciences is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prescott Medical Communications Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Three Rivers Pharmaceuticals is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.